OPRX

AI Memo

OptimizeRx

As of 2026-10-10/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

OpenPath inventory availability • 2026-12-31

Base target: $9 / p=50% prob

Biggest risk

The required second-half revenue step-up is substantial against a 30% Q2 year-over-year decline and 90% net revenue retention. A small number of large customers account for much of the weakness, while new-product revenue remains unquantified. Company Q2 results.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

If second-half revenue reaches guidance and OpenPath creates measurable advertiser demand, platform distribution could support improved growth. Management reported Q2 revenue and adjusted EBITDA above consensus, without quantifying the beat in its release. Company Q2 results.

Research note

Recommendation

—

Confidence

medium

As of

2026-10-10

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-half revenue required to meet 2026 guidance
Audience-builder commercial conversion
If second-half revenue reaches guidance and OpenPath creates measurable advertiser demand, platform distribution could support improved growth.

BearKey bullets

A planned CFO transition effective January 1, 2027 adds an execution item to monitor, although the company describes it as planned succession [#SEC-8K-2026-08-12].
Meeting 2026 revenue guidance requires approximately $54.65 million–$59.65 million of second-half revenue after $40.35 million in the first half.
Company Q2 results.

WatchKey bullets

OpenPath inventory availability

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $9 (p=50%)

Target spread vs base: +31% / -38%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $9 (p=50%)Bear Target: $6 (p=25%)

Commentary

September product and distribution announcements are constructive, but neither quantifies revenue conversion. One reported September 29 analyst target increase is a limited revision signal; a comprehensive post-Q2 revision series and a verified announcement-linked price reaction were unavailable. The numeric sentiment fields are unavailable-data placeholders, not observed readings. Low coverage and weak forward-demand visibility warrant monitoring rather than a strong bullish call.

As of 2026-10-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-half revenue required to meet 2026 guidance
Audience-builder commercial conversion

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-10-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
OpenPath inventory availability
OptimizeRx expects its EHR advertising inventory to become available to advertisers using The Trade Desk through OpenPath in Q4 2026. The company says its network reaches 800,000 verified healthcare professionals; advertiser uptake and revenue contribution remain unquantified [#PR-2026-09-22]. Company announcement.
Prob 70.00% • Move 8.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Second-half revenue required to meet 2026 guidance
2026-12-31
First-half revenue was $40.35 million, so reaffirmed full-year guidance of $95 million–$100 million requires approximately $54.65 million–$59.65 million in the second half. Q2 revenue fell 30% year over year, and net revenue retention declined to 90%. Management said Q2 revenue and adjusted EBITDA exceeded consensus, but the company release does not quantify that surprise. Results were reported under Item 2.02 [#8-K-2026-08-12]. Company Q2 results.
Prob 55% • Move 12% • Priced-in 55%

Long-term Catalysts

Months to a year

Audience-builder commercial conversion
2027-12-31
OptimizeRx expanded its Natural Language Audience Builder to create healthcare-professional and consumer audiences in one workflow. Paid adoption and incremental revenue were not quantified in the announcement, making commercial conversion the key test [#PR-2026-09-14]. Company announcement.
Prob 45% • Move 15% • Priced-in 25%

Risks

A planned CFO transition effective January 1, 2027 adds an execution item to monitor, although the company describes it as planned succession [#SEC-8K-2026-08-12].
Meeting 2026 revenue guidance requires approximately $54.65 million–$59.65 million of second-half revenue after $40.35 million in the first half. Company Q2 results.
OpenPath availability and audience-builder functionality do not yet establish paid uptake or incremental revenue. OpenPath announcement; audience-builder announcement.
Q2 revenue declined 30% year over year; net revenue retention fell to 90% from 121%, highlighting customer-demand and concentration risk. Company Q2 results.

Peers

Symbol	Summary
ABT	Broad healthcare-sector reference only; its scale and medical-device portfolio make it unsuitable as a direct valuation peer for OptimizeRx's pharmaceutical marketing technology business.
INGN	Similar market-cap candidate, but its medical-device business differs materially from OptimizeRx's advertising and audience-technology model; not a direct valuation comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-10

Loading AI feed…

Symbol

Summary

ABT

Broad healthcare-sector reference only; its scale and medical-device portfolio make it unsuitable as a direct valuation peer for OptimizeRx's pharmaceutical marketing technology business.

INGN

Similar market-cap candidate, but its medical-device business differs materially from OptimizeRx's advertising and audience-technology model; not a direct valuation comparable.